NxStage Medical, Inc. (NXTM) Shares Bought by Principal Financial Group Inc.

Principal Financial Group Inc. lifted its position in NxStage Medical, Inc. (NASDAQ:NXTM) by 36.6% in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 38,510 shares of the medical device company’s stock after acquiring an additional 10,319 shares during the quarter. Principal Financial Group Inc. owned approximately 0.06% of NxStage Medical worth $965,000 as of its most recent filing with the SEC.

Several other large investors have also recently modified their holdings of the stock. FMR LLC lifted its position in shares of NxStage Medical by 1.9% in the 1st quarter. FMR LLC now owns 7,482,201 shares of the medical device company’s stock valued at $200,747,000 after acquiring an additional 137,399 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of NxStage Medical by 8.5% in the 1st quarter. Vanguard Group Inc. now owns 5,273,762 shares of the medical device company’s stock valued at $141,495,000 after acquiring an additional 412,233 shares in the last quarter. BlackRock Inc. lifted its position in shares of NxStage Medical by 38,360.4% in the 1st quarter. BlackRock Inc. now owns 4,413,326 shares of the medical device company’s stock valued at $118,408,000 after acquiring an additional 4,401,851 shares in the last quarter. William Blair Investment Management LLC lifted its position in shares of NxStage Medical by 491.6% in the 2nd quarter. William Blair Investment Management LLC now owns 1,959,318 shares of the medical device company’s stock valued at $49,120,000 after acquiring an additional 1,628,114 shares in the last quarter. Finally, State Street Corp lifted its position in shares of NxStage Medical by 2.3% in the 1st quarter. State Street Corp now owns 1,236,803 shares of the medical device company’s stock valued at $33,182,000 after acquiring an additional 28,103 shares in the last quarter. Institutional investors and hedge funds own 92.66% of the company’s stock.

In other NxStage Medical news, SVP Winifred L. Swan sold 3,500 shares of NxStage Medical stock in a transaction that occurred on Tuesday, August 15th. The shares were sold at an average price of $29.21, for a total value of $102,235.00. Following the transaction, the senior vice president now owns 16,270 shares of the company’s stock, valued at $475,246.70. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Matthew W. Towse sold 4,300 shares of NxStage Medical stock in a transaction that occurred on Thursday, July 20th. The shares were sold at an average price of $24.16, for a total transaction of $103,888.00. Following the completion of the transaction, the senior vice president now directly owns 28,721 shares in the company, valued at approximately $693,899.36. The disclosure for this sale can be found here. In the last ninety days, insiders sold 50,400 shares of company stock worth $1,406,020. Insiders own 4.70% of the company’s stock.

Several equities research analysts recently commented on NXTM shares. Craig Hallum started coverage on shares of NxStage Medical in a research report on Tuesday, June 27th. They issued a “buy” rating and a $32.00 price target for the company. BidaskClub upgraded shares of NxStage Medical from a “hold” rating to a “buy” rating in a research report on Friday, June 30th. Leerink Swann downgraded shares of NxStage Medical from an “outperform” rating to a “market perform” rating and upped their price target for the company from $28.00 to $30.00 in a research report on Tuesday, August 22nd. Stephens downgraded shares of NxStage Medical from an “overweight” rating to an “equal weight” rating and reduced their price target for the company from $33.00 to $30.00 in a research report on Wednesday, August 9th. Finally, William Blair downgraded shares of NxStage Medical from an “outperform” rating to a “market perform” rating in a research report on Monday, August 7th. Two equities research analysts have rated the stock with a sell rating and eight have issued a hold rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $30.25.

NxStage Medical, Inc. (NASDAQ NXTM) opened at 27.54 on Wednesday. The firm has a 50-day moving average of $27.77 and a 200 day moving average of $25.84. The firm’s market cap is $1.82 billion. NxStage Medical, Inc. has a 1-year low of $20.45 and a 1-year high of $30.80.

NxStage Medical (NASDAQ:NXTM) last announced its quarterly earnings results on Monday, August 7th. The medical device company reported ($0.03) earnings per share for the quarter, meeting the Zacks’ consensus estimate of ($0.03). NxStage Medical had a negative net margin of 1.33% and a negative return on equity of 2.43%. The firm had revenue of $92.20 million for the quarter, compared to analyst estimates of $96.47 million. During the same quarter in the previous year, the firm posted ($0.03) earnings per share. The business’s revenue was up .0% on a year-over-year basis. Analysts expect that NxStage Medical, Inc. will post ($0.05) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “NxStage Medical, Inc. (NXTM) Shares Bought by Principal Financial Group Inc.” was published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this piece of conten

Several other large investors have also recently modified their holdings of the stock. FMR LLC lifted its position in shares of NxStage Medical by 1.9% in the 1st quarter. FMR LLC now owns 7,482,201 shares of the medical device company’s stock valued at $200,747,000 after acquiring an additional 137,399 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of NxStage Medical by 8.5% in the 1st quarter. Vanguard Group Inc. now owns 5,273,762 shares of the medical device company’s stock valued at $141,495,000 after acquiring an additional 412,233 shares in the last quarter. BlackRock Inc. lifted its position in shares of NxStage Medical by 38,360.4% in the 1st quarter. BlackRock Inc. now owns 4,413,326 shares of the medical device company’s stock valued at $118,408,000 after acquiring an additional 4,401,851 shares in the last quarter. William Blair Investment Management LLC lifted its position in shares of NxStage Medical by 491.6% in the 2nd quarter. William Blair Investment Management LLC now owns 1,959,318 shares of the medical device company’s stock valued at $49,120,000 after acquiring an additional 1,628,114 shares in the last quarter. Finally, State Street Corp lifted its position in shares of NxStage Medical by 2.3% in the 1st quarter. State Street Corp now owns 1,236,803 shares of the medical device company’s stock valued at $33,182,000 after acquiring an additional 28,103 shares in the last quarter. Institutional investors and hedge funds own 92.66% of the company’s stock.

In other NxStage Medical news, SVP Winifred L. Swan sold 3,500 shares of NxStage Medical stock in a transaction that occurred on Tuesday, August 15th. The shares were sold at an average price of $29.21, for a total value of $102,235.00. Following the transaction, the senior vice president now owns 16,270 shares of the company’s stock, valued at $475,246.70. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Matthew W. Towse sold 4,300 shares of NxStage Medical stock in a transaction that occurred on Thursday, July 20th. The shares were sold at an average price of $24.16, for a total transaction of $103,888.00. Following the completion of the transaction, the senior vice president now directly owns 28,721 shares in the company, valued at approximately $693,899.36. The disclosure for this sale can be found here. In the last ninety days, insiders sold 50,400 shares of company stock worth $1,406,020. Insiders own 4.70% of the company’s stock.

Several equities research analysts recently commented on NXTM shares. Craig Hallum started coverage on shares of NxStage Medical in a research report on Tuesday, June 27th. They issued a “buy” rating and a $32.00 price target for the company. BidaskClub upgraded shares of NxStage Medical from a “hold” rating to a “buy” rating in a research report on Friday, June 30th. Leerink Swann downgraded shares of NxStage Medical from an “outperform” rating to a “market perform” rating and upped their price target for the company from $28.00 to $30.00 in a research report on Tuesday, August 22nd. Stephens downgraded shares of NxStage Medical from an “overweight” rating to an “equal weight” rating and reduced their price target for the company from $33.00 to $30.00 in a research report on Wednesday, August 9th. Finally, William Blair downgraded shares of NxStage Medical from an “outperform” rating to a “market perform” rating in a research report on Monday, August 7th. Two equities research analysts have rated the stock with a sell rating and eight have issued a hold rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $30.25.

NxStage Medical, Inc. (NASDAQ NXTM) opened at 27.54 on Wednesday. The firm has a 50-day moving average of $27.77 and a 200 day moving average of $25.84. The firm’s market cap is $1.82 billion. NxStage Medical, Inc. has a 1-year low of $20.45 and a 1-year high of $30.80.

NxStage Medical (NASDAQ:NXTM) last announced its quarterly earnings results on Monday, August 7th. The medical device company reported ($0.03) earnings per share for the quarter, meeting the Zacks’ consensus estimate of ($0.03). NxStage Medical had a negative net margin of 1.33% and a negative return on equity of 2.43%. The firm had revenue of $92.20 million for the quarter, compared to analyst estimates of $96.47 million. During the same quarter in the previous year, the firm posted ($0.03) earnings per share. The business’s revenue was up .0% on a year-over-year basis. Analysts expect that NxStage Medical, Inc. will post ($0.05) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “NxStage Medical, Inc. (NXTM) Shares Bought by Principal Financial Group Inc.” was published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of U.S. & international copyright laws. The legal version of this piece of content can be viewed at https://ledgergazette.com/2017/10/11/nxstage-medical-inc-nxtm-shares-bought-by-principal-financial-group-inc.html.

NxStage Medical Profile

NxStage Medical, Inc is a medical technology company. The Company develops, manufactures and markets products and services for patients suffering from chronic or acute kidney failure. It operates through three segments. The System One segment includes revenues from the sale and rental of the System One and PureFlow SL dialysate preparation equipment and the sale of disposable products in the home and critical care markets.

Want to see what other hedge funds are holding NXTM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NxStage Medical, Inc. (NASDAQ:NXTM).

Institutional Ownership by Quarter for NxStage Medical (NASDAQ:NXTM)

Receive News & Ratings for NxStage Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply